Ribo Advances Development of Dual Targeting siRNA SR122 for Dyslipidemia in European Clinical Trials

Ribo Submits European Clinical Trial Application for SR122

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have made significant strides in the field of lipid disorders by submitting a clinical trial application (CTA) for the innovative dual-targeting siRNA, SR122. Designed to tackle severe dyslipidemia, including hypertriglyceridemia, this development marks a critical step in Ribo's ongoing strategy to expand its treatment options for lipid metabolism disorders.

The Significance of SR122

The SR122 siRNA is unique in its approach to lipid management, targeting two clinically validated pathways: ApoC3 and PCSK9. These molecules play vital roles in lipid metabolism, and by simultaneously influencing them, SR122 aims to provide a more effective treatment solution. This dual targeting has the potential to lead to significant improvements in various lipid parameters and cardiometabolic risk factors, offering patients a differentiated treatment option.

As dyslipidemia continues to be a global health challenge and a major risk factor for cardiovascular diseases, it is crucial to develop effective treatments. Current lipid-lowering therapies often leave patients with residual cardiovascular risk. The advent of SR122 could offer new hope, particularly for those suffering from severe hypertriglyceridemia, who are at heightened risk of acute pancreatitis.

Clinical Trial Design

The phase I clinical trial for SR122 is structured as a randomized, placebo-controlled study. It is designed to assess several key factors: safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug, administered via subcutaneous injection to healthy participants. This will be the first time the double-targeting approach of SR122 is evaluated in humans, promising to generate essential data for its future development.

Dr. Anders Gabrielsen, Ribo's Chief Medical Officer, expressed optimism regarding the SR122's potential. He highlighted the synergistic benefits of inhibiting both ApoC3 and PCSK9, noting that this approach could significantly reduce lipid-associated risks for patients, heralding a transformative change in risk management for those affected by severe hypertriglyceridemia.

Next Steps in Development

The outcome of the phase I trial will be instrumental in guiding further clinical development of SR122 among target populations. As Ribo progresses with phase II studies of its lead lipid-active candidate, RBD5044, the company remains committed to enhancing its product offerings in lipid management, reinforcing its position at the forefront of this critical healthcare area.

This latest initiative underscores Ribo's dedication to addressing unmet medical needs in the treatment of lipid disorders and its ambition to innovate within the biopharmaceutical landscape. With its promising dual-targeting approach, SR122 holds the potential to change the lives of many patients grappling with challenging lipid conditions.